Dr. Garassino on QoL Findings from the FLAURA Study in NSCLC

Marina Chiara Garassino, MD, medical consultant in the Medical Oncology Division, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, discusses the quality of life findings from the FLAURA study in non—small cell lung cancer (NSCLC) during the 2018 European Lung Cancer Congress, which is a joint collaboration between ESMO and the IASLC.

The phase III FLAURA trial comparing the third-generation tyrosine kinase inhibitor (TKI) osimertinib (Tagrisso) with a first-generation TKI gefitinib (Iressa) in patients with treatment-naïve EGFR-positive NSCLC. Results showed a progression-free survival of 19.4 months with osimertinib, which is superior to that of gefitinib, says Garassino. Additionally, osimertinib was very well tolerated.

Results on the QoL of these patients showed similar results between those who received osimertinib and those who received gefitinib. This suggests that these drugs are very active in this setting and they work very quickly, says Garassino.

Osimertinib, which currently approved in the second-line setting for patients who harbor the T790M resistance mutation, has been granted an FDA priority review designation for a first-line indication.